Gilead Sciences announced that the China National Drug Administration has approved Genvoya for the treatment of HIV-1 infection. Genvoya is the first TAF-based single tablet regimen for the treatment of HIV to be approved in China. Genvoya is indicated in China as a complete regimen for the treatment of adults and adolescents infected with HIV-1 without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. In the United States, Genvoya has a boxed warning in its product label regarding the risks of post treatment acute exacerbation of hepatitis B.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.